215 related articles for article (PubMed ID: 29933385)
1. Testosterone treatment and the risk of aggressive prostate cancer in men with low testosterone levels.
Walsh TJ; Shores MM; Krakauer CA; Forsberg CW; Fox AE; Moore KP; Korpak A; Heckbert SR; Zeliadt SB; Kinsey CE; Thompson ML; Smith NL; Matsumoto AM
PLoS One; 2018; 13(6):e0199194. PubMed ID: 29933385
[TBL] [Abstract][Full Text] [Related]
2. Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy.
Rhoden EL; Morgentaler A
Int J Impot Res; 2006; 18(2):201-5. PubMed ID: 16177827
[TBL] [Abstract][Full Text] [Related]
3. Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men.
Debruyne FM; Behre HM; Roehrborn CG; Maggi M; Wu FC; Schröder FH; Jones TH; Porst H; Hackett G; Wheaton OA; Martin-Morales A; Meuleman E; Cunningham GR; Divan HA; Rosen RC;
BJU Int; 2017 Feb; 119(2):216-224. PubMed ID: 27409523
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
[TBL] [Abstract][Full Text] [Related]
5. Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial.
Bhasin S; Travison TG; Pencina KM; O'Leary M; Cunningham GR; Lincoff AM; Nissen SE; Lucia MS; Preston MA; Khera M; Khan N; Snabes MC; Li X; Tangen CM; Buhr KA; Thompson IM
JAMA Netw Open; 2023 Dec; 6(12):e2348692. PubMed ID: 38150256
[TBL] [Abstract][Full Text] [Related]
6. Is testosterone treatment good for the prostate? Study of safety during long-term treatment.
Feneley MR; Carruthers M
J Sex Med; 2012 Aug; 9(8):2138-49. PubMed ID: 22672563
[TBL] [Abstract][Full Text] [Related]
7. [Testosterone and the prostate].
Sperling H; Rossi R; Lümmen G; Rübben H
Urologe A; 2004 Sep; 43(9):1092-6. PubMed ID: 15368045
[TBL] [Abstract][Full Text] [Related]
8. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy.
Pastuszak AW; Pearlman AM; Lai WS; Godoy G; Sathyamoorthy K; Liu JS; Miles BJ; Lipshultz LI; Khera M
J Urol; 2013 Aug; 190(2):639-44. PubMed ID: 23395803
[TBL] [Abstract][Full Text] [Related]
9. Testosterone treatment in hypogonadal men: prostate-specific antigen level and risk of prostate cancer.
Guay AT; Perez JB; Fitaihi WA; Vereb M
Endocr Pract; 2000; 6(2):132-8. PubMed ID: 11421528
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of Prostate Biopsy in Men with Hypogonadism Prior or During Testosterone Replacement Therapy.
Shoskes DA; Barazani Y; Fareed K; Sabanegh E
Int Braz J Urol; 2015; 41(6):1167-71. PubMed ID: 26742976
[TBL] [Abstract][Full Text] [Related]
11. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia.
Rhoden EL; Morgentaler A
J Urol; 2003 Dec; 170(6 Pt 1):2348-51. PubMed ID: 14634413
[TBL] [Abstract][Full Text] [Related]
12. Use of testosterone replacement therapy in the United States and its effect on subsequent prostate cancer outcomes.
Kaplan AL; Hu JC
Urology; 2013 Aug; 82(2):321-6. PubMed ID: 23706552
[TBL] [Abstract][Full Text] [Related]
13. [Testosterone replacement therapy and prostate cancer. The current position 67 years after the Huggins myth].
Rinnab L; Gust K; Hautmann RE; Küfer R
Urologe A; 2009 May; 48(5):516-22. PubMed ID: 19296069
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen testing in hypogonadism: implications for the safety of testosterone-replacement therapy.
Gould DC; Feneley MR; Kirby RS
BJU Int; 2006 Jul; 98(1):1-4. PubMed ID: 16831134
[TBL] [Abstract][Full Text] [Related]
15. The effect of testosterone replacement therapy on prostate-specific antigen (PSA) levels in men being treated for hypogonadism: a systematic review and meta-analysis.
Kang DY; Li HJ
Medicine (Baltimore); 2015 Jan; 94(3):e410. PubMed ID: 25621688
[TBL] [Abstract][Full Text] [Related]
16. The effect of testosterone replacement therapy on prostate cancer: a systematic review and meta-analysis.
Cui Y; Zong H; Yan H; Zhang Y
Prostate Cancer Prostatic Dis; 2014 Jun; 17(2):132-43. PubMed ID: 24445948
[TBL] [Abstract][Full Text] [Related]
17. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial.
Marks LS; Mazer NA; Mostaghel E; Hess DL; Dorey FJ; Epstein JI; Veltri RW; Makarov DV; Partin AW; Bostwick DG; Macairan ML; Nelson PS
JAMA; 2006 Nov; 296(19):2351-61. PubMed ID: 17105798
[TBL] [Abstract][Full Text] [Related]
18. Testosterone Replacement Therapy and the Risk of Prostate Cancer in Men With Late-Onset Hypogonadism.
Santella C; Renoux C; Yin H; Yu OHY; Azoulay L
Am J Epidemiol; 2019 Sep; 188(9):1666-1673. PubMed ID: 31145457
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less.
Morgentaler A; Rhoden EL
Urology; 2006 Dec; 68(6):1263-7. PubMed ID: 17169647
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment.
Raynaud JP; Gardette J; Rollet J; Legros JJ
BJU Int; 2013 May; 111(6):880-90. PubMed ID: 23294726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]